Compugen (CGEN) investor relations material

Company overview and platform

• Focuses on computational AI-based target discovery for immuno-oncology, with a validated platform that has produced multiple first-in-class assets and drug candidates.

• Pipeline includes wholly owned assets such as COM902 and an Fc-reduced TIGIT blocker, as well as a PVRIG blocker antibody (COM701).

• Assets have been licensed to major pharma partners, including AstraZeneca and Gilead, with ongoing clinical trials and collaborations.

COM701 clinical development and trial design

• COM701, an anti-PVRIG antibody, is being evaluated as a maintenance therapy in platinum-sensitive ovarian cancer, targeting patients with unmet needs.

• Demonstrated durable responses and safety in PD-1 negative, platinum-resistant ovarian cancer patients, with plans to move into earlier, platinum-sensitive settings.

• Adaptive trial design: 40 patients receive COM701, 20 receive placebo; primary endpoint is progression-free survival (PFS), with results expected in Q1 2027.

• Interim analysis will provide quantitative PFS data, with a three-month improvement over control considered clinically meaningful.

• Flexibility to expand the trial, pursue accelerated approval, or initiate pivotal studies based on interim results.

Competitive landscape and differentiation

• COM701 is differentiated from discontinued competitors by its Fc-reduced design, aiming to avoid depletion of key immune cells and enhance T cell activity.

• Only a few competitors remain in the PVRIG space, with BioNTech as a notable example.